Endovascular management of acute thoracic aortic emergencies

Acute emergencies involving the descending thoracic aorta, such as traumatic aortic disruption (TAD), ruptured descending thoracic aneurysm (RDTA), complicated type B dissection (cTBD), have been particularly challenging for aortic surgeons. Many patients do not survive the initial event, and are never afforded the opportunity to undergo surgical repair. Emergent open operative repair of the descending thoracic aorta, the traditional gold standard, is a formidable undertaking with significant operative mortality and morbidity. These are some of the most difficult and highest risk procedures performed by vascular surgeons.

Since the approval of the first thoracic endograft in 2005, thoracic endovascular aortic repair (TEVAR) has quickly become the treatment of choice for elective thoracic aortic aneurysm repair. It was not long before the “off-label” use of TEVAR for a wide variety of conditions, both elective and emergent, was reported. The expanded use of TEVAR has resulted in a decrease in both operative mortality and morbidity for patients with a wide variety of aortic pathologies. In addition, hospital length of stay is usually less following TEVAR, especially if the procedure is done using a totally percutaneous technique.

**KEYWORDS:** TEVAR; thoracic aorta emergencies

Acute emergencies involving the descending thoracic aorta, such as traumatic aortic disruption (TAD), ruptured descending thoracic aneurysm (RDTA), complicated type B dissection (cTBD), have been particularly challenging for aortic surgeons. Many patients do not survive the initial event, and are never afforded the opportunity to undergo surgical repair. Emergent open operative repair of the descending thoracic aorta, the traditional gold standard, is a formidable undertaking with significant operative mortality and morbidity. These are some of the most difficult and highest risk procedures performed by vascular surgeons.

Since the approval of the first thoracic endograft in 2005, thoracic endovascular aortic repair (TEVAR) has quickly become the treatment of choice for elective thoracic aortic aneurysm repair. It was not long before the “off-label” use of TEVAR for a wide variety of conditions, both elective and emergent, was reported. The expanded use of TEVAR has resulted in a decrease in both operative mortality and morbidity for patients with a wide variety of aortic pathologies. In addition, hospital length of stay is usually less following TEVAR, especially if the procedure is done using a totally percutaneous technique.

The use of TEVAR in the emergency setting requires a level of commitment and logistics that not all institutions can provide. Appropriate inventories of endografts, as well as full-time availability of a hybrid endovascular suite and team, are required. In addition, open surgical back-up is required. These resources may not be available in all centers, particularly those with low TEVAR volumes. In 2011 we reported our single center experience of 44 consecutive patients undergoing emergent TEVAR for descending thoracic aortic catastrophes over a three-year period [1].

During that time no patient required emergent open repair of the descending thoracic aorta. The technical success rate was 100%, with 84% survival and a procedure related complication rate of 20%. These results compare favorable to those seen with open surgical repair.

Endograft technology has improved remarkably since then, along with the skills of the surgeons performing these procedures. The use of TEVAR for both elective and emergent conditions involving the descending thoracic aorta has increased dramatically. This brief review describes the current state of the art for the treatment of emergency conditions involving the descending thoracic aorta.

**Traumatic aortic disruption**

Open surgical repair of TAD is associated with an operative mortality approaching 30%
TEVAR demonstrating a significant decrease in mortality, morbidity and hospital length of stay. Open repair of RDTA has a reported mortality rate of 25% to 45% [13-15]. Several recent studies comparing TEVAR to open repair for RDTA show unadjusted mortality rates for TEVAR of 18% to 23% [12,16,17]. The incidence of paraplegia was also less than that seen with open repair. As with TEVAR for TAD, coverage of the left subclavian artery is often necessary. Because these patients are usually unstable, preoperative subclavian revascularization is not performed.

Despite being older and having a greater burden of associated comorbidities than patients undergoing open repair, patients undergoing TEVAR are more likely to be routinely discharged home following surgery [16]. Interestingly, small hospitals had worse results compared to large hospital for open repair, but not for TEVAR [16]. This suggests that emergent TEVAR may be particularly well suited for smaller centers not having a large experience with open thoracic aneurysm repair.

Complicated type B aortic dissection
While the role and benefits of TEVAR in the treatment of TAD and RDTA are well defined, its efficacy in the treatment of aortic dissection is less clear. In the acute period the most common indications for TEVAR are cTBD with rupture and cTBD with end organ malperfusion. When treating cTBD with rupture, the primary entry site and the ruptured segment both must be covered by the endograft. Technical success rates of 100% with no operative deaths have been reported [18]. This compares favorably to historic mortality of 50% for open surgical repair [19]. When performing TEVAR for malperfusion associated with cTBD, the primary entry site must be covered in order to increase flow in the true lumen and facilitate thrombosis of the false lumen. Stenting of branch vessels is sometimes required. Technical success rates of 100% with 99% survival have been reported [20].

Less frequent conditions
TEVAR has been used to treat a variety of other less common emergent conditions involving the descending thoracic aorta. Hemorrhage from a penetrating aortic ulcer is treated similarly to RDTA. Mycotic aneurysms [21], aorto-oesophageal fistulae,8 and aortobronchial fistulae [22] have been successfully treated using TEVAR.
At this point TEVAR should be considered as a temporizing measure for these infectious conditions, although there are isolated reports of successful long-term treatment with TEVAR.

In conclusion, TEVAR has become the technique of choice for the treatment of a wide variety of emergent conditions involving the descending thoracic aorta. The same benefits seen with elective TEVAR are observed in the emergent setting. As endograft technology continues to evolve and improve, the role of TEVAR in the emergency setting will continue to expand.

REFERENCES